Didn't participate at #EuroMedlab2019? You find more information about our workshop and poster below.
Plasma Calprotectin: a promising early biomarker for diagnosis of bacterial infections and sepsis
Gentian hosted the Educational Workshop “Plasma Calprotectin: a promising early biomarker for diagnosis of bacterial infections and sepsis”. The workshop was well attended, and two speakers were invited, Dr. Jordi Rello, MD, PhD (Spain) and Dr. Toralph Ruge, MD, PhD (Sweden). Dr. Aleksandra Havelka, PhD (Sweden) presented Dr. Ruge’s talk.
The talks discussed calprotectin and other biomarkers’ role in diagnosis of severe infections and sepsis. The presentations showed studies and results supporting the ability of calprotectin to discriminate patients with acute infections from patients with other states of inflammatory responses, including patients with heart failure, chronic obstructive pulmonary disease and asthma presented in the emergency department setting. Highlights include:
Calprotectin is an independent predictor of 28-day mortality in septic patients and promising biomarker in early diagnosis, risk stratification, and evaluation of prognosis in septic patients 
Calprotectin is an accurate marker of sepsis in very low birth weight newborns 
Calprotectin has significant diagnostic accuracy for the bacterial etiology of sepsis 
1 Gao, S. et al (2015) Am J Emerg Med 33 1278–1282 2Terrin et al (2011), Clin Dev Immunol.; 2011:291085 3Bartáková E.et al (2019) Diagnostic Microbiol Infect Dis, 219-226
Calprotectin, a promising biomarker for diagnosis of respiratory tract infections
Gentian also presented the poster “Calprotectin, a promising biomarker for diagnosis of respiratory tract infections”. The poster shows results that indicate that calprotectin is superior to HBP in differentiation between viral and bacterial infections. Also, Calprotectin is superior to procalcitonin in differentiation between viral infections, and Streptococcal tonsillitis or Mycoplasma infections.
Gentian Diagnostics AS is pleased to proclaim its successful participation at the 23rd IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine, EuroMedLab 2019 in Barcelona, Spain. Dr. Hilja Ibert, CEO of Gentian Diagnostics AS says; “We are pleased to have participated at EuroMedLab 2019. The high level of interest from the congress participants for our new GCAL biomarker has been encouraging. We feel confident in our strategic focus on innovations that improve laboratory and clinical efficiency.